Version June 2024
Intraoperative miosis: Ophthalmic: Instill 1 drop every 30 minutes, beginning 2 hours prior to surgery for a total of 4 drops in each affected eye.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Cardiovascular: Hyperemia (ocular)
Hematologic & oncologic: Hemorrhagic diathesis (ocular tissue; in conjunction with ocular surgery)
Ophthalmic: Anterior chamber eye hemorrhage, burning sensation of eyes (transient), eye irritation, miosis, mydriasis, stinging of eyes (transient)
Miscellaneous: Fibrosis (ocular)
Hypersensitivity to flurbiprofen or any component of the formulation.
Concerns related to adverse effects:
• Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to aspirin or other NSAIDs, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin.
• Bleeding/hemostasis: May increase bleeding time associated with ocular surgery. Use with caution in patients with known bleeding tendencies or those receiving anticoagulants.
• Delayed healing: Healing time may be slowed or delayed.
Special populations:
• Post-surgical patients: To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as sodium:
Generic: 0.03% (2.5 mL)
Yes
Solution (Flurbiprofen Sodium Ophthalmic)
0.03% (per mL): $17.28
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For ophthalmic use only; avoid contact of bottle tip with skin or eye. Separate bottles should be used for each eye if both eyes require treatment.
Intraoperative miosis: Inhibition of intraoperative miosis
Flurbiprofen may be confused with fenoprofen.
Ocufen may be confused with Ocuflox.
Ocufen [US, Canada, and multiple international markets] may be confused with Ocupres brand name for timolol [India]; Ocupress brand name for dorzolamide [Brazil].
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Anticoagulants: Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy
Corticosteroids (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Risk C: Monitor therapy
Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic). Risk C: Monitor therapy
Adverse events were observed following systemic administration of flurbiprofen in animal reproduction studies. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).
It is not known if flurbiprofen is present in breast milk following ophthalmic administration. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.
Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties
Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
